Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,379 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.
Hanafusa N, Isoai A, Ishihara T, Inoue T, Ishitani K, Utsugisawa T, Yamaka T, Ito T, Sugiyama H, Arakawa A, Yamada Y, Itano Y, Onodera H, Kobayashi R, Torii N, Numata T, Kashiwabara T, Matsuno Y, Kato M. Hanafusa N, et al. Among authors: ito t. PLoS One. 2017 May 16;12(5):e0177303. doi: 10.1371/journal.pone.0177303. eCollection 2017. PLoS One. 2017. PMID: 28510606 Free PMC article.
Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Yamaguchi H, Kitayama J, Emoto S, Ishigami H, Ito T, Hanafusa N, Watanabe T. Yamaguchi H, et al. Among authors: ito t. Eur J Surg Oncol. 2015 Jul;41(7):875-80. doi: 10.1016/j.ejso.2015.04.013. Epub 2015 May 8. Eur J Surg Oncol. 2015. PMID: 25986856
Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study.
Ishitani K, Isoai A, Ito T, Sugiyama H, Arakawa A, Yamada Y, Onodera H, Kobayashi R, Torii N, Soneda N, Matsuno Y, Utsugisawa T, Kato M, Hanafusa N. Ishitani K, et al. Among authors: ito t. Int J Clin Oncol. 2021 Jun;26(6):1130-1138. doi: 10.1007/s10147-021-01883-2. Epub 2021 Mar 24. Int J Clin Oncol. 2021. PMID: 33761026
Optimal Paracentesis Volume for Terminally Ill Cancer Patients With Ascites.
Ito T, Yokomichi N, Ishiki H, Kawaguchi T, Masuda K, Tsukuura H, Funaki H, Suzuki K, Oya K, Nakagawa J, Mori M, Yamaguchi T. Ito T, et al. J Pain Symptom Manage. 2021 Nov;62(5):968-977. doi: 10.1016/j.jpainsymman.2021.04.010. Epub 2021 Apr 29. J Pain Symptom Manage. 2021. PMID: 33933616
Effect of paracentesis on the survival of patients with terminal cancer and ascites: a propensity score-weighted analysis of the East Asian Collaborative Cross-cultural Study to Elucidate the Dying Process.
Masuda K, Ishiki H, Yokomichi N, Yamaguchi T, Ito T, Takatsu H, Amano K, Hiramoto S, Yamauchi T, Kawaguchi T, Mori M, Matsuda Y, Yamaguchi T. Masuda K, et al. Among authors: ito t. Support Care Cancer. 2022 Jul;30(7):6233-6241. doi: 10.1007/s00520-022-07057-8. Epub 2022 Apr 21. Support Care Cancer. 2022. PMID: 35449369
11,379 results
You have reached the last available page of results. Please see the User Guide for more information.